|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TCERG1L |
Gene summary for TCERG1L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TCERG1L | Gene ID | 256536 |
| Gene name | transcription elongation regulator 1 like | |
| Gene Alias | TCERG1L | |
| Cytomap | 10q26.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q5VWI1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 256536 | TCERG1L | male-WTA | Human | Thyroid | PTC | 2.51e-56 | 6.81e-01 | 0.1037 |
| 256536 | TCERG1L | PTC01 | Human | Thyroid | PTC | 1.78e-39 | 1.05e+00 | 0.1899 |
| 256536 | TCERG1L | PTC04 | Human | Thyroid | PTC | 1.30e-09 | 3.47e-01 | 0.1927 |
| 256536 | TCERG1L | PTC05 | Human | Thyroid | PTC | 3.63e-23 | 1.45e+00 | 0.2065 |
| 256536 | TCERG1L | PTC06 | Human | Thyroid | PTC | 2.63e-59 | 1.68e+00 | 0.2057 |
| 256536 | TCERG1L | PTC07 | Human | Thyroid | PTC | 4.16e-59 | 1.20e+00 | 0.2044 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TCERG1L | SNV | Missense_Mutation | rs769852465 | c.878N>A | p.Arg293Gln | p.R293Q | Q5VWI1 | protein_coding | deleterious(0.03) | possibly_damaging(0.478) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| TCERG1L | SNV | Missense_Mutation | novel | c.1016N>G | p.Pro339Arg | p.P339R | Q5VWI1 | protein_coding | deleterious(0) | possibly_damaging(0.597) | TCGA-AR-A2LM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| TCERG1L | SNV | Missense_Mutation | rs145173247 | c.1061N>A | p.Arg354Gln | p.R354Q | Q5VWI1 | protein_coding | deleterious(0) | possibly_damaging(0.644) | TCGA-E2-A14S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
| TCERG1L | SNV | Missense_Mutation | rs761569207 | c.799N>T | p.Arg267Cys | p.R267C | Q5VWI1 | protein_coding | tolerated(1) | benign(0) | TCGA-E9-A1N4-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| TCERG1L | insertion | Frame_Shift_Ins | novel | c.457_458insA | p.Ser153LysfsTer9 | p.S153Kfs*9 | Q5VWI1 | protein_coding | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TCERG1L | SNV | Missense_Mutation | rs750665045 | c.1127G>A | p.Arg376His | p.R376H | Q5VWI1 | protein_coding | deleterious(0.01) | benign(0.206) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TCERG1L | SNV | Missense_Mutation | rs144481929 | c.790N>A | p.Val264Met | p.V264M | Q5VWI1 | protein_coding | tolerated(0.09) | benign(0.035) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| TCERG1L | SNV | Missense_Mutation | c.878N>C | p.Arg293Pro | p.R293P | Q5VWI1 | protein_coding | deleterious(0) | possibly_damaging(0.615) | TCGA-C5-A1M5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| TCERG1L | SNV | Missense_Mutation | rs761955297 | c.619N>T | p.Pro207Ser | p.P207S | Q5VWI1 | protein_coding | tolerated(0.08) | benign(0.388) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| TCERG1L | SNV | Missense_Mutation | c.1400C>T | p.Ser467Leu | p.S467L | Q5VWI1 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |